Reaction
Breast Inflammation reporting signals
As of the last recalculation, Breast Inflammation appears in 301 FAERS reports alongside 5 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 58.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ado-Trastuzumab Emtansine | 7 | 58.8 | 58.8 |
| Ribociclib | 24 | 57.1 | 57.1 |
| Minocycline | 7 | 42.5 | 42.5 |
| Pertuzumab | 11 | 29.0 | 29.0 |
| Fam-Trastuzumab Deruxtecan-Nxki | 3 | 20.8 | 20.8 |